ImmunoGuard

a standardized fixed combination of Andrographis paniculata Nees, with Eleutherococcus senticosus Maxim, Schizandra chinensis Bail. and Glycyrrhiza glabra L. extracts in patients with Familial Mediterranean Fever.

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Tian, Fangyuan: 1 article (01/2022)
2.	Wu, Bin: 1 article (01/2022)
3.	Xu, Ting: 1 article (01/2022)
4.	Yin, Xi: 1 article (01/2022)

Related Diseases

1.	Drug-Related Side Effects and Adverse Reactions 01/01/2022 - "However, the four studies of ImmunoGuard, rilonacept, anakinra and canakinumab were generally well-designed.  We aimed to report on the number of participants experiencing an attack, the timing of attacks, the prevention of amyloid A amyloidosis, adverse drug reactions and the response of a number of biochemical markers from the acute phase of an attack; but no study reported on the prevention of amyloid A amyloidosis. "
2.	Acute-Phase Reaction 01/01/2022 - "ImmunoGuard versus placebo The ImmunoGuard study observed there are probably no differences in adverse effects (moderate-certainty evidence) or in acute-phase response indicators after one month of treatment (moderate-certainty evidence). "

Related Drugs and Biologics

1.	Interleukin 1 Receptor Antagonist Protein (Anakinra)
2.	Biomarkers (Surrogate Marker)
3.	canakinumab
4.	rilonacept
5.	AA amyloidosis